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Abstract
Barriers to global tuberculosis (TB) control include multidrug resistance, HIV infection, and weak
health systems. Case detection is critical to TB control and is affected by all three of these. Currently,
most low- and middle-income countries (LMICs) rely on direct sputum smear microscopy for
diagnosis. Modern culture methods and molecular tests, previously considered too complex or too
expensive for implementation in LMICs, are now being introduced there in parallel with a global
effort to strengthen laboratories. It remains to be seen whether services based on these tools can be
made widely accessible to patients. New point-of-care tests for TB are urgently needed but cannot be
expected in the near future. In the meantime, diagnostic tools based on optimized smear microscopy,
although less sensitive than reference laboratory tests, may be more accessible and have more impact
on case finding. It is a matter of urgency that these improved microscopy services be integrated with
services based on rapid methods that can identify multidrug-resistant cases.
Introduction and context
In 2006, there were an estimated 9.2 million new cases of
tuberculosis (TB), the majority occurring in low- and
middle-income countries (LMICs) [1]. Diagnosing TB on
the basis of clinical and radiological findings alone is
known to be inaccurate, particularly in HIV-associated
TB [2,3]. The definitive diagnosis is bacteriological. Most
LMICs rely almost entirely on direct sputum smear
microscopy (DSSM) for routine TB diagnostic services.
This involves the examination of a series of sputum
specimens from each patient and requires repeated
patient visits to health facilities to submit specimens
and to collect results. International guidelines exist for
the DSSM-based diagnosis and management of TB
suspects, and patients and most countries have adopted
these in their national programmes [4,5]. International
efforts to control TB, largely based on DSSM, ensure that
millions of patients receive treatment and hundreds of
thousands of lives are saved each year, but so far these
efforts have failed to substantially reduce the annual
global incidence [1]. Three major barriers to global TB
control have been identified: the weak health systems
that exist in many countries, the growing resistance of
Mycobacterium tuberculosis (MTB) to the currently used
anti-TB drugs, and HIV infection [1].
It is also recognized that inadequate case finding is a
major obstacle to global TB control [1]. This inadequacy
may be considered both quantitative and qualitative.
Case finding may be inadequate, quantitatively, in
failing to identify the majority of those in the community
with TB. In many countries in recent decades, HIV has
compromised quantitative case finding by altering the
clinical presentation of TB and mitigating the immuno-
logical reaction to infection, which in turn results in a
lower sputum bacillary load [6]. Case finding may also
be considered qualitatively inadequate in failing to
distinguish between TB cases with and without critical
patterns of drug resistance that impact upon treatment
success and continued transmission. Both forms of
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frankly broken health systems that exist in many
countries. They are also exacerbated by widespread
poverty in LMICs. Many poor people who need to be
investigated for TB are unable to afford repeated visits to
health facilities for smear diagnosis, and frequently
default during the diagnosis process [7]. Services, based
on new tools, that can be delivered within resource-poor
health systems, that are sensitive to the poverty of many
service users, and that result in the increased identifica-
tion of HIV-associated and drug-resistant TB cases, could
make a major contribution to global TB control.
Recent advances
Currently, all bacteriological diagnostic tests for TB rely
upon microscopically visualizing the characteristic acid-
fast bacilli in specially stained sputum smears, growing
and identifying MTB in cultures ofspecimens, or detecting
MTB-specific nucleic acids in specimens. Diagnosis
through MTB culture or nucleic acid detection is more
sensitivethanDSSM,andparticularlysoinHIV-associated
TB, in which DSSM is notoriously insensitive [8]. These
techniques also have the benefit of making isolates or
nucleic acids available for drug susceptibility testing. A
disadvantage of these tests is that they take considerably
longer than smear microscopy for a result to be available
for the management of the patient. This may be because
the test itself takes several weeks to complete (culture)
and/or because it requires a sophisticated bio-safe
laboratory and, unavoidably, a centralized service of
some kind. Centralized services and the logistics involved
in specimen transport and delivering laboratory reports
within a clinically useful time frame are particularly
difficult to organize within weak health systems [9,10].
Where these tests have been introducedat the National TB
Reference Laboratory (NRL) level, they have been asso-
ciated with limited impact on TB case management [10].
Integrating new TB diagnostic tools in
resource-poor settings
Until recently, modern culture methods and nucleic acid
detection tests have been considered either too complex
or too expensive for implementation in LMICs outside of
NRLs. In the past two years, the World Health Organiza-
tion has endorsed the use of both liquid culture systems
(plus new rapid methods for identifying isolates) and
molecular line-probe assays for TB control in LMICs
[11,12]. There are now considerable global efforts under
way to assist National TB Programs (NTPs) in LMICs to
build laboratory capacity to introduce these new tools
and develop services based on them [13]. It is recognized
that that there is no strong evidence that the introduction
of these tools will actually improve TB control at the
routine programmatic level. Field studies and cost-
effectiveness data are needed to better understand the
real-world implications of the changes [14]. There are
considerable challenges involved in delivering services
based on these technologies in LMICs. These challenges
are well recognized, but with little prospect that technol-
ogyplatformswillbecomeavailableinthenearfutureand
thus obviate the need for greatly increased laboratory
capability/capacity, there is an imperative to act now.
The Retooling Task Force and the New Diagnostics
Working Group of the Stop TB Partnership recently
described the pipeline of new diagnostic tools for TB
[15]. Of eight new tools considered to be in late-stage
development and perhaps available within the next few
years, one is a nucleic acid detection test (which may be
simpler than current line-probe assays for drug resistance
detection) and four are culture-based diagnostics. Of the
remaining three tools in late-stage development, two are
based on improved smear microscopy. The remaining
tool is the interferon-gamma release assay, which
(though available on the market) has not yet been
endorsed by the World Health Organization for use in TB
control programmes, as there is considerable uncertainty
about its likely contribution to case finding in LMICs
[16]. The two improved microscopy tools, being appro-
priate for the lower levels of poor health services, may
have considerably more impact on quantitative case
finding in LMICs than either the culture methods or the
molecular assays. One of the improved microscopy tools
is fluorescent microscopy (FM) systems based on
inexpensive battery-powered light-emitting diodes
(LEDs) for DSSM [17]. In a recent systematic review,
FM was found to have comparable specificity to Ziehl-
Neelsen DSSM but with an approximately 10% increase
in sensitivity while taking around 25% of the time to
examine smears [18]. The benefits for case finding and
alleviating heavy workloads in laboratories have not
been realizable to date since conventional fluorescence
microscopes were complex and very expensive. The LED-
FM systems are currently under evaluation in a number
of LMICs. The other improved microscopy tool, front-
loaded microscopy, is an approach rather than a
technological change [19]. A systematic review of the
yield of serial sputum specimens has reported that the
first two specimens (collected as spot and morning)
identify 95–98% of all smear-positive cases [20]. Because
a considerable proportion of patients default from the
current DSSM diagnostic process (that requires multiple
patient visits), front-loaded smear microscopy involves
collecting and examining two sputum specimens on the
first day a patient presents and referring those patients in
whom the sputum is smear-positive immediately for
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settings
Current tools for diagnosing TB in resource-poortreatment.Multi-countrytrialsoffront-loadedmicroscopy
are ongoing. These optimized smear microscopy tools,
though less sensitive than reference laboratory tests, may
bemoreaccessibleandhaveagreaterpublichealthimpact
[21]. However, they will not identify drug resistance.
Implications for clinical practice
Using new tools to improve diagnostic services for
TB in resource-poor settings
Diagnostic services based on new tools, whether new (or
modified) technologies or new approaches to delivery,
have the potential to revolutionize TB case finding. The
deficiencies in both quantitative and qualitative case
findings need to be addressed. Diagnostic services need to
identify more TB cases and to identify drug-resistant
cases. Such services are unlikely, in the foreseeable future,
to be based upon the introduction of a single new
diagnostic tool. Rather, they will involve multiple tools
being implemented in an integrated way within a tiered
health system [15]. The new diagnostic tools, as well as
being integrated with the health systems, will need to be
carefullyintegratedwithalgorithmsfortheclinicalmanage-
ment of cases. Simple new tools for the diagnosis of
pulmonary TB at the lowest levels of health services
(point-of-care) and for the diagnosis of extrapulmonary
and childhood TB are also urgently needed. They are not
yet on the horizon.
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